Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

• 主要な著者: Mei-Zi Wang (著者), Jie Wang (著者), Dong-Wei Cao (著者), Yue Tu (著者), Bu-Hui Liu (著者), Can-Can Yuan (著者), Huan Li (著者), Qi-Jun Fang (著者), Jia-Xin Chen (著者), Yan Fu (著者), Bing-Ying Wan (著者), Zi-Yue Wan (著者), Yi-Gang Wan (著者), Guo-Wen Wu (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....